#59 - What’s next for obesity care in the GLP-1 era - Kim Boyd - Weight Watchers

What if we treated obesity not as a failure of willpower, but as the complex, chronic medical condition it truly is?

With over half of the global adult population expected to be living with overweight or obesity by 2035, according to the World Obesity Federation, traditional "eat less, exercise more" advice has proven fundamentally insufficient. The widespread arrival of GLP-1 receptor agonists has marked a dramatic shift in metabolic care, offering unprecedented efficacy in weight management, diabetes treatment, and cardiovascular risk reduction.

Yet, as these therapies gain global momentum, critical questions remain around their long-term management, side effect mitigation, and equitable access.

Among those leading the charge toward comprehensive, patient-centered care is Dr. Kim Boyd, Chief Medical Officer at Weight Watchers. A primary care doctor trained in integrative medicine and an early leader at One Medical, Kim sits at the intersection of modern pharmacology, behavioral science, and digital health technology.

In this episode of Impulse, Kim breaks down the pathophysiology of obesity as a chronic disease associated with over 200 health conditions across the cardiovascular, renal, and metabolic (CVRM) spectrum. We explore the rapidly expanding therapeutic landscape—from established injectables like Wegovy and Zepbound to oral formulations, amylin combinations, and muscle-sparing agents in the pipeline. Kim shares why medications alone are not a magic bullet and details how companion digital programs, strength training, and tailored nutrition are essential to preserving muscle functionality and achieving lasting health outcomes.

We also discuss how digital health tools and AI can distill overwhelming physiological data into daily actionable habits, the challenges of global health coverage and pricing dynamics, and the future of sustainable obesity management.

A timely and eye-opening conversation on the evolution of metabolic health and the future of comprehensive obesity care!

Timeline:

• 00:00:00 - Kim's background and role as Chief Medical Officer at Weight Watchers
• 00:04:15 - Redefining obesity as a chronic medical condition
• 00:15:05 - Mapping the therapeutic landscape: GLP-1s, oral formulations, and pipeline agents
• 00:24:00 - Managing side effects, preserving muscle functionality, and the role of companion care
• 00:27:50 - Integrating AI, wearables, and digital health into Weight Watchers' companion programs
• 00:39:50 - Global access barriers, generic availability, and the future of sustainable obesity care

What we also talked about with Kim:

• Saxenda
• Orforglipron
• CagriSema
• Retatrutide
• Amylin
• Body Mass Index (BMI)
• Continuous Glucose Monitors (CGMs)
• Bariatric surgery

This episode was made possible with the support of HLTH Europe!

As mentioned by Kim during the episode, we invite you to read Ground Truths by Dr. Eric Topol and his recent book Super Agers, offering exhaustive and evidence-based insights on the science of longevity.

Kim recommends following the work and upcoming book “Food Is Medicine” by Cardiologist and Nutrition Scientist Dr. Dariush Mozaffarian.

You can also check out the research and publications by NIH Nutrition Scientist Dr. Kevin Hall on metabolic regulation and energy balance.

You can get in touch with Kim via LinkedIn, and follow Weight Watchers’ activities on their website, LinkedIn, Facebook, Instagram, X, and YouTube.

If you want to give me feedback on the episode or suggest potential guests, contact me on LinkedIn or via email!

And if you liked the episode, please share it, subscribe to the podcast, and leave a 5-star review on streaming platforms!

You can also support my work by making a PayPal donation @ImpulsePodcast!

Lastly, don’t forget to follow our activities on LinkedIn and our website!